CAR T-cell therapy updates in CLL

Susan O’Brien, MD, of the University of California, Irvine, CA, tells about a Phase I/II trial which investigated the use of defined CD4 and CD8 CAR T-cell products in the treatment of chronic lymphocytic leukemia (CLL). This interview took place at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands. Dr O'brien goes on to explain how response rates were very positive and toxicities were reduced.